TD Cowen analyst Oliver Chen lowered the firm’s price target on Beauty Health to $9 from $15 and keeps an Outperform rating on the shares. The firm said the 2Q print was mixed. Results were better than expected and FY23 revenue guide was reiterated. However worse than expected GM compression from addressing Syndeo’s technical issues in the US and a higher mix of refurbished machines weighed on adjusted EBITDA margins.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SKIN:
- The Beauty Health (NASDAQ:SKIN) Glows On Healthy Q2 Numbers
- Beauty Health backs FY23 revenue view $460M-$480M, consensus $461.57M
- Beauty Health reports Q2 EPS 3c, consensus 5c
- Beauty Health CFO Liyuan Woo leaves, Michael Monahan succeeds
- Short Report: Carvana short squeeze sends bearish position to 2023 lows